Large-cap Health Care company Takeda Pharmaceutical has logged a -1.5% change today on a trading volume of 449,758. The average volume for the stock is 1,796,693.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. Based in Tokyo, Japan the company has 49,095 full time employees and a market cap of $44,911,276,032. Takeda Pharmaceutical currently offers its equity investors a dividend that yields 1276.9% per year.
The company is now trading -22.77% away from its average analyst target price of $18.38 per share. The 3 analysts following the stock have set target prices ranging from $17.18 to $19.98, and on average give Takeda Pharmaceutical a rating of buy.
Over the last 12 months TAK shares have declined by -12.6%, which represents a difference of -44.2% when compared to the S&P 500. The stock's 52 week high is $17.15 per share and its 52 week low is $13.19. With its net margins declining an average -5.4% over the last 5 years, Takeda Pharmaceutical declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 4,027,480,000 | 317,038,000 | 8 | 33.33 |
| 2022 | 3,569,010,000 | 230,166,000 | 6 | -50.0 |
| 2021 | 3,197,810,000 | 376,171,000 | 12 | 1100.0 |
| 2020 | 3,291,190,000 | 44,290,000 | 1 | -83.33 |
| 2019 | 2,097,220,000 | 135,080,000 | 6 | -45.45 |
| 2018 | 1,770,530,000 | 186,708,000 | 11 | n/a |
